{"title":"AAV9 Vectors","description":"\u003cp\u003eReady-to-use AAV9 vectors for blood–brain-barrier-crossing CNS, heart, and muscle gene delivery — qPCR-titered and in stock.\u003c\/p\u003e","products":[{"product_id":"aav-null-aav-serotype-9-bhv21500052","title":"AAV-Null (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500052\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe null (empty) transgene contains no functional payload, making this vector ideal as a matched delivery and promoter control.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168487277,"sku":"SL100839-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168520045,"sku":"SL100839-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500052_aav-null-aav-serotype-9_SL100839.jpg?v=1770796189"},{"product_id":"aav-gfp-aav-serotype-9-bhv21500053","title":"AAV-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500053\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168552813,"sku":"SL100840-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168585581,"sku":"SL100840-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500053_aav-gfp-aav-serotype-9_SL100840.png?v=1770796189"},{"product_id":"scaav-gfp-aav-serotype-9-self-complementary-bhv21500054","title":"scAAV-GFP (AAV Serotype 9, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500054\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168618349,"sku":"SL100840-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168651117,"sku":"SL100840-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500054_scaav-gfp-aav-serotype-9-self-complementary_SL100840-SC.png?v=1770796189"},{"product_id":"aav-cre-aav-serotype-9-bhv21500055","title":"AAV-Cre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500055\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168683885,"sku":"SL100841-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168716653,"sku":"SL100841-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500055_aav-cre-aav-serotype-9_SL100841.png?v=1770796190"},{"product_id":"scaav-cre-aav-serotype-9-self-complementary-bhv21500056","title":"scAAV-Cre (AAV Serotype 9, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500056\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168749421,"sku":"SL100841-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168782189,"sku":"SL100841-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500056_scaav-cre-aav-serotype-9-self-complementary_SL100841-SC.png?v=1770796190"},{"product_id":"aav-cre-gfp-aav-serotype-9-cre-co-expression-with-gfp-bhv21500057","title":"AAV-Cre-GFP (AAV Serotype 9, Cre co-expression with GFP)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500057\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168814957,"sku":"SL100842-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168847725,"sku":"SL100842-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500057_aav-cre-gfp-aav-serotype-9-cre-co-expression-with-gfp_SL100842.png?v=1770796190"},{"product_id":"aav-u6-shrna-scramble-gfp-aav-serotype-9-bhv21500058","title":"AAV-U6-shRNA(Scramble)-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(Scramble)-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eU6 Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500058\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eU6 is an RNA Pol III promoter used specifically to express short non-coding RNAs such as shRNA; it does not drive protein-coding transgenes. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168880493,"sku":"SL100843-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168913261,"sku":"SL100843-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500058_aav-u6-shrna-scramble-gfp-aav-serotype-9_SL100843.png?v=1770796191"},{"product_id":"aav-cag-gfp-aav-serotype-9-bhv21500059","title":"AAV-CAG-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500059\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020168946029,"sku":"SL100844-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020168978797,"sku":"SL100844-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500059_aav-cag-gfp-aav-serotype-9_SL100844.png?v=1770796191"},{"product_id":"aav-synapsin-gfp-aav-serotype-9-bhv21500060","title":"AAV-Synapsin-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500060\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169011565,"sku":"SL100845-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169044333,"sku":"SL100845-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500060_aav-synapsin-gfp-aav-serotype-9_SL100845.png?v=1770796191"},{"product_id":"scaav-synapsin-gfp-aav-serotype-9-self-complementary-bhv21500061","title":"scAAV-Synapsin-GFP (AAV Serotype 9, Self-complementary)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003escAAV-Synapsin-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500061\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169077101,"sku":"SL100845-SC-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169109869,"sku":"SL100845-SC-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500061_scaav-synapsin-gfp-aav-serotype-9-self-complementary_SL100845-SC.png?v=1770796192"},{"product_id":"aav-cag-chr2-venus-aav-serotype-9-bhv21500067","title":"AAV-CAG-ChR2-Venus (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChR2-Venus\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500067\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eChR2-Venus is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChR2\u003c\/strong\u003e. A \u003cstrong\u003eVenus + YFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020169503085,"sku":"SL100851-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020169535853,"sku":"SL100851-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500067_aav-cag-chr2-venus-aav-serotype-9_SL100851.png?v=1770796194"},{"product_id":"aav-mrfp-aav-serotype-9-bhv21500078","title":"AAV-mRFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-mRFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500078\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003emRFP is the encoded payload for this construct. A \u003cstrong\u003emRFP + RFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mRFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170387821,"sku":"SL100867-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170420589,"sku":"SL100867-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500078_aav-mrfp-aav-serotype-9_SL100867.png?v=1770796198"},{"product_id":"aav-lacz-aav-serotype-9-bhv21500079","title":"AAV-LacZ (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-LacZ\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500079\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eLacZ is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: LacZ-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170453357,"sku":"SL100868-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170486125,"sku":"SL100868-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500079_aav-lacz-aav-serotype-9_SL100868.png?v=1770796198"},{"product_id":"aav-cag-chief-tdtomato-aav-serotype-9-bhv21500080","title":"AAV-CAG-ChIEF-tdTOMATO (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-ChIEF-tdTOMATO\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500080\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eOptogenetic vectors encode light-sensitive ion channels or pumps that allow millisecond-precision control of neuronal activity with light, enabling causal interrogation of neural circuits. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eChIEF-tdTOMATO is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eChIEF\u003c\/strong\u003e. A \u003cstrong\u003etdTomato\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eOptogenetics\u003c\/li\u003e\n\u003cli\u003eNeural circuit interrogation\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow adequate time for opsin expression before stimulation (typically 2–4 weeks in vivo for AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eConfirm opsin expression with reporter fluorescence before initiating light delivery.\u003c\/li\u003e\n\u003cli\u003eUse appropriate light parameters (wavelength, power, pulse duration) validated for the specific opsin.\u003c\/li\u003e\n\u003cli\u003eInclude non-light-stimulated and vector-only controls to separate expression effects from optogenetic effects.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020170518893,"sku":"SL100869-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020170551661,"sku":"SL100869-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500080_aav-cag-chief-tdtomato-aav-serotype-9_SL100869.png?v=1770796198"},{"product_id":"aav-cag-shrna-scramble-aav-serotype-9-bhv21500090","title":"AAV-CAG-shRNA(Scramble) (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-shRNA(Scramble)\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500090\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171174253,"sku":"SL100885-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171207021,"sku":"SL100885-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500090_aav-cag-shrna-scramble-aav-serotype-9_SL100885.jpg?v=1770796202"},{"product_id":"aav-synapsin-cre-aav-serotype-9-bhv21500093","title":"AAV-Synapsin-Cre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Synapsin-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500093\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171338093,"sku":"SL100888-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171370861,"sku":"SL100888-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500093_aav-synapsin-cre-aav-serotype-9_SL100888.png?v=1770796203"},{"product_id":"aav-syn-cre-gfp-aav-serotype-9-cre-fusion-with-gfp-bhv21500097","title":"AAV-Syn-Cre-GFP (AAV Serotype 9, Cre fusion with GFP)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500097\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171600237,"sku":"SL100892-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171633005,"sku":"SL100892-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500097_aav-syn-cre-gfp-aav-serotype-9-cre-fusion-with-gfp_SL100892.jpg?v=1770796204"},{"product_id":"aav-cag-cre-gfp-aav-serotype-9-bhv21500098","title":"AAV-CAG-Cre-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500098\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171665773,"sku":"SL100893-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171698541,"sku":"SL100893-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500098_aav-cag-cre-gfp-aav-serotype-9_SL100893.png?v=1770796204"},{"product_id":"aav-u6-shrna-scramble-ef1a-gfp-aav-serotype-9-bhv21500099","title":"AAV-U6-shRNA(scramble)-EF1a-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-U6-shRNA(scramble)-EF1a-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eEF1α + U6 (dual) Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500099\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eEF1α drives protein-coding transgene expression while U6 drives shRNA, enabling combined gene delivery and RNA interference in a single vector. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eThe shRNA payload drives RNA interference to silence target genes at the post-transcriptional level. The sensor\/actuator encoded is \u003cstrong\u003eRNAi (shRNA\/miRNA)\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eRNA interference\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eValidate knockdown efficiency by qPCR or Western blot at your target timepoint.\u003c\/li\u003e\n\u003cli\u003eConfirm GFP co-expression (if present) to assess transduction efficiency before measuring knockdown.\u003c\/li\u003e\n\u003cli\u003eInclude scramble-shRNA controls injected at the same dose to control for non-specific effects.\u003c\/li\u003e\n\u003cli\u003eMonitor for off-target effects using appropriate transcriptomic or phenotypic readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020171731309,"sku":"SL100894-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020171764077,"sku":"SL100894-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500099_aav-u6-shrna-scramble-ef1a-gfp-aav-serotype-9_SL100894.png?v=1770796205"},{"product_id":"aav-mcherry-aav-serotype-9-bhv21500114","title":"AAV-mCherry (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-mCherry\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500114\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172779885,"sku":"SL101129-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172812653,"sku":"SL101129-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500114_aav-mcherry-aav-serotype-9_SL101129.png?v=1770796210"},{"product_id":"aav-hsyn-dio-gfp-aav-serotype-9-bhv21500116","title":"AAV-hSyn-DIO-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-hSyn-DIO-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500116\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eDIO-GFP is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eRecombinase\u003c\/strong\u003e. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003eCre-dependent (DIO\/FLEX)\u003c\/strong\u003e—the transgene is inverted and silenced by default, and flips into the active orientation only in cells expressing Cre recombinase. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eCre-driver dependent expression\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) Cre-driver-negative animals injected with the same DIO vector to confirm absence of leaky expression; (2) driver-positive animals without vector injection to confirm no background from the driver alone; (3) a Cre-expressing positive-control line to validate recombination efficiency; and (4) assay-matched functional or anatomical readouts to confirm payload activity only in driver-positive, vector-injected animals.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172910957,"sku":"SL101132-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020172943725,"sku":"SL101132-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500116_aav-hsyn-dio-gfp-aav-serotype-9_SL101132.png?v=1770796211"},{"product_id":"aav-cag-cre-aav-serotype-9-bhv21500117","title":"AAV-CAG-Cre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500117\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eCre recombinase catalyzes site-specific recombination at loxP sites, enabling activation or deletion of conditional alleles.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020172976493,"sku":"SL101135-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020173009261,"sku":"SL101135-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500117_aav-cag-cre-aav-serotype-9_SL101135.png?v=1770796211"},{"product_id":"aav-cmv-sacas9-u6-sgrna-scramble-aav-serotype-9-bhv21500119","title":"AAV-CMV-saCas9-U6-sgRNA(Scramble) (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-saCas9-U6-sgRNA(Scramble)\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV + U6 (dual) Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500119\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThis vector uses a dual-promoter design: CMV drives protein-coding transgene expression while U6 drives shRNA expression, enabling simultaneous gene delivery and knockdown. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003esaCas9-U6-sgRNA is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003esaCas9\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: saCas9-U6-sgRNA-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020173140333,"sku":"SL101137-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020173173101,"sku":"SL101137-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500119_aav-cmv-sacas9-u6-sgrna-scramble-aav-serotype-9_SL101137.png?v=1770796212"},{"product_id":"aav-cmv-hcas9-aav-serotype-9-bhv21500158","title":"AAV-CMV-hCas9 (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-hCas9\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500158\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003ehCas9 is the encoded payload for this construct. The sensor\/actuator encoded is \u003cstrong\u003eCas9\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCRISPR genome editing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: hCas9-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020175892845,"sku":"SL101404-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020175925613,"sku":"SL101404-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500158_aav-cmv-hcas9-aav-serotype-9_SL101404.png?v=1770796229"},{"product_id":"aav-cag-icre-aav-serotype-9-bhv21500164","title":"AAV-CAG-iCre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-iCre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500164\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176286061,"sku":"SL101413-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176318829,"sku":"SL101413-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500164_aav-cag-icre-aav-serotype-9_SL101413.png?v=1770796231"},{"product_id":"aav-cag-flpo-aav-serotype-9-bhv21500168","title":"AAV-CAG-FLPo (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-FLPo\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500168\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020176548205,"sku":"SL101417-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020176580973,"sku":"SL101417-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500168_aav-cag-flpo-aav-serotype-9_SL101417.png?v=1770796232"},{"product_id":"aav-amhc-gfp-serotype-9-bhv21500175","title":"AAV-aMHC-GFP (Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-aMHC-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eaMHC Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500175\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eaMHC (alpha myosin heavy chain) targets cardiomyocytes and is used for cardiac-specific gene modulation. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eaMHC-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cardiomyocyte-restricted expression in cardiac tissue.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: aMHC-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177006957,"sku":"SL101430-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177039725,"sku":"SL101430-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500175_aav-amhc-gfp-serotype-9_SL101430.png?v=1770796235"},{"product_id":"aav-amhc-cre-aav-serotype-9-bhv21500176","title":"AAV-aMHC-Cre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-aMHC-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eaMHC Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500176\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eaMHC (alpha myosin heavy chain) targets cardiomyocytes and is used for cardiac-specific gene modulation. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eaMHC-Cre is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cardiomyocyte-restricted expression in cardiac tissue.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177072493,"sku":"SL101431-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177105261,"sku":"SL101431-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500176_aav-amhc-cre-aav-serotype-9_SL101431.png?v=1770796235"},{"product_id":"aav-cmv-icre-aav-serotype-9-bhv21500183","title":"AAV-CMV-iCre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-iCre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500183\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177564013,"sku":"SL101439-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177596781,"sku":"SL101439-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500183_aav-cmv-icre-aav-serotype-9_SL101439.png?v=1770796237"},{"product_id":"aav-cag-luc-aav-serotype-9-bhv21500184","title":"AAV-CAG-Luc (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Luc\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500184\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020177629549,"sku":"SL101440-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020177662317,"sku":"SL101440-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500184_aav-cag-luc-aav-serotype-9_SL101440.png?v=1770796238"},{"product_id":"aav-syn-icre-aav-serotype-9-bhv21500190","title":"AAV-Syn-iCre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-iCre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500190\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eiCre is an improved Cre recombinase with reduced CpG content, designed to minimize immune responses in vivo.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178022765,"sku":"SL101446-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178055533,"sku":"SL101446-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500190_aav-syn-icre-aav-serotype-9_SL101446.png?v=1770796240"},{"product_id":"aav-syn-flpo-aav-serotype-9-bhv21500196","title":"AAV-Syn-FLPo (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Syn-FLPo\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eSynapsin Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500196\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe Synapsin (hSyn) promoter is a compact neuronal promoter that restricts expression to post-mitotic neurons, making it a standard choice for CNS work. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to post-mitotic neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178415981,"sku":"SL101452-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178448749,"sku":"SL101452-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500196_aav-syn-flpo-aav-serotype-9_SL101452.png?v=1770796242"},{"product_id":"aav-cmv-flpo-aav-serotype-9-bhv21500204","title":"AAV-CMV-FLPo (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-FLPo\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500204\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eFLPo is a codon-optimized Flp recombinase for FRT-based intersectional strategies.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: FLPo-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020178940269,"sku":"SL101460-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020178973037,"sku":"SL101460-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500204_aav-cmv-flpo-aav-serotype-9_SL101460.png?v=1770796244"},{"product_id":"aav-ctnt-gfp-aav-serotype-9-bhv21500209","title":"AAV-cTNT-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-cTNT-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003ecTNT Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500209\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003ecTNT (cardiac troponin T) provides highly selective cardiomyocyte expression, supporting precise cardiac gene delivery studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003ecTNT-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cardiomyocyte-restricted expression in cardiac tissue.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: cTNT-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179267949,"sku":"SL101466-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179300717,"sku":"SL101466-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500209_aav-ctnt-gfp-aav-serotype-9_SL101466.png?v=1770796246"},{"product_id":"aav-ctnt-null-aav-serotype-9-bhv21500210","title":"AAV-cTNT-Null (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-cTNT-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003ecTNT Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500210\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003ecTNT (cardiac troponin T) provides highly selective cardiomyocyte expression, supporting precise cardiac gene delivery studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003ecTNT-Null is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cardiomyocyte-restricted expression in cardiac tissue.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: cTNT-Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179333485,"sku":"SL101467-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179366253,"sku":"SL101467-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500210_aav-ctnt-null-aav-serotype-9_SL101467.png?v=1770796246"},{"product_id":"aav-amhc-null-aav-serotype-9-bhv21500211","title":"AAV-aMHC-Null (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-aMHC-Null\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eaMHC Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500211\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eaMHC (alpha myosin heavy chain) targets cardiomyocytes and is used for cardiac-specific gene modulation. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eaMHC-Null is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for cardiomyocyte-restricted expression in cardiac tissue.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: aMHC-Null-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020179399021,"sku":"SL101468-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020179431789,"sku":"SL101468-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500211_aav-amhc-null-aav-serotype-9_SL101468.png?v=1770796247"},{"product_id":"aav-cag-gcamp6s-aav-serotype-9-bhv21500221","title":"AAV-CAG-GCaMP6s (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GCaMP6s\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500221\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGCaMP6s is a sensitive genetically encoded calcium indicator for imaging neuronal activity at single-cell resolution. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/9 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180054381,"sku":"SL101478-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180087149,"sku":"SL101478-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500221_aav-cag-gcamp6s-aav-serotype-9_SL101478.png?v=1770796250"},{"product_id":"aav-cag-gcamp6m-aav-serotype-9-bhv21500222","title":"AAV-CAG-GCaMP6m (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GCaMP6m\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500222\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGCaMP6m balances speed and sensitivity for calcium imaging of neural populations. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/9 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180119917,"sku":"SL101479-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180152685,"sku":"SL101479-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500222_aav-cag-gcamp6m-aav-serotype-9_SL101479.png?v=1770796251"},{"product_id":"aav-cag-gcamp6f-aav-serotype-9-bhv21500223","title":"AAV-CAG-GCaMP6f (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-GCaMP6f\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500223\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGCaMP6f is a fast calcium indicator for tracking rapid action potential-linked calcium transients. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/9 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180185453,"sku":"SL101480-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180218221,"sku":"SL101480-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500223_aav-cag-gcamp6f-aav-serotype-9_SL101480.png?v=1770796251"},{"product_id":"aav-camkii-gcamp6m-aav-serotype-9-bhv21500224","title":"AAV-CaMKII-GCaMP6m (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CaMKII-GCaMP6m\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCaMKII Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500224\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eGenetically encoded calcium indicators (GECIs) such as GCaMP permit real-time imaging of neuronal activity and calcium dynamics in vivo with single-cell resolution. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCaMKII targets expression to excitatory neurons, particularly in the hippocampus and cortex, for region-specific manipulation of excitatory circuits. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGCaMP6m balances speed and sensitivity for calcium imaging of neural populations. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression targeted to excitatory neurons.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCalcium imaging\u003c\/li\u003e\n\u003cli\u003eNeuronal activity recording\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow 2–4 weeks post-injection for stable sensor expression with AAV2\/9 in vivo.\u003c\/li\u003e\n\u003cli\u003eConfirm baseline fluorescence and responsiveness to depolarizing stimuli before experimental sessions.\u003c\/li\u003e\n\u003cli\u003eMinimize photobleaching with low-power excitation and limit imaging duration.\u003c\/li\u003e\n\u003cli\u003eUse functional controls (KCl, field stimulation) to validate sensor responsiveness in your preparation.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180250989,"sku":"SL101481-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180283757,"sku":"SL101481-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500224_aav-camkii-gcamp6m-aav-serotype-9_SL101481.png?v=1770796252"},{"product_id":"aav-tre-gfp-aav-serotype-9-bhv21500225","title":"AAV-TRE-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-TRE-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eTRE-Tight Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500225\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eTRE-Tight is a tetracycline-responsive element used in Tet-inducible systems; transgene expression is OFF by default and activated by doxycycline or rtTA. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eTRE-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is controlled by the \u003cstrong\u003eTet-inducible TRE system\u003c\/strong\u003e—transgene transcription is off by default and activated by administration of doxycycline or co-expression of rtTA. The promoter is designed for cell-type specificity determined by the co-expressed Cre driver.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003cli\u003eInducible expression (Tet system)\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: TRE-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) no-doxycycline controls to confirm absence of leaky expression; (2) rtTA-negative animals with vector injection to confirm dependence on the transactivator; (3) dose-response characterization of doxycycline titration in your model; and (4) appropriate washout experiments to confirm reversibility of expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180316525,"sku":"SL101482-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180349293,"sku":"SL101482-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500225_aav-tre-gfp-aav-serotype-9_SL101482.png?v=1770796252"},{"product_id":"aav-cmv-luc-aav-serotype-9-bhv21500234","title":"AAV-CMV-Luc (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-Luc\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500234\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eLuciferase enables bioluminescence imaging for non-invasive in vivo tracking of transduction and gene expression. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020180939117,"sku":"SL101494-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020180971885,"sku":"SL101494-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500234_aav-cmv-luc-aav-serotype-9_SL101494.png?v=1770796255"},{"product_id":"aav-luc-pest-aav-serotype-9-bhv21500236","title":"AAV-Luc-PEST (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-Luc-PEST\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500236\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eLuc-PEST is the encoded payload for this construct. A \u003cstrong\u003eLuciferase\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Luc-PEST-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181070189,"sku":"SL101496-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181102957,"sku":"SL101496-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500236_aav-luc-pest-aav-serotype-9_SL101496.png?v=1770796255"},{"product_id":"aav-tre-cre-aav-serotype-9-bhv21500241","title":"AAV-TRE-Cre (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-TRE-Cre\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eTRE-Tight Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500241\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecombinase vectors (Cre, Flp, and variants) enable conditional genome editing through site-specific recombination, supporting intersectional strategies, lineage tracing, and conditional knockouts. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eTRE-Tight is a tetracycline-responsive element used in Tet-inducible systems; transgene expression is OFF by default and activated by doxycycline or rtTA. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eTRE-Cre is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is controlled by the \u003cstrong\u003eTet-inducible TRE system\u003c\/strong\u003e—transgene transcription is off by default and activated by administration of doxycycline or co-expression of rtTA. The promoter is designed for cell-type specificity determined by the co-expressed Cre driver.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCre\/loxP recombination\u003c\/li\u003e\n\u003cli\u003eConditional genetics\u003c\/li\u003e\n\u003cli\u003eLineage tracing\u003c\/li\u003e\n\u003cli\u003eInducible expression (Tet system)\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eConfirm Cre\/recombinase-driver expression in target cells before injection.\u003c\/li\u003e\n\u003cli\u003eAllow sufficient time for recombination to occur (typically 1–3 weeks post-injection with AAV2\/9).\u003c\/li\u003e\n\u003cli\u003eValidate recombination efficiency with a reporter allele before proceeding to experimental readouts.\u003c\/li\u003e\n\u003cli\u003eInclude driver-negative animals as genetic negative controls.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) no-doxycycline controls to confirm absence of leaky expression; (2) rtTA-negative animals with vector injection to confirm dependence on the transactivator; (3) dose-response characterization of doxycycline titration in your model; and (4) appropriate washout experiments to confirm reversibility of expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181397869,"sku":"SL101512-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181430637,"sku":"SL101512-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500241_aav-tre-cre-aav-serotype-9_SL101512.png?v=1770796257"},{"product_id":"aav-tmck-gfp-aav-serotype-9-bhv21500242","title":"AAV-tMCK-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-tMCK-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003etMCK Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500242\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe tMCK (truncated muscle creatine kinase) promoter restricts expression to striated muscle, supporting skeletal and cardiac muscle targeting. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003etMCK-GFP is the encoded payload for this construct. A \u003cstrong\u003eGFP\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression restricted to skeletal muscle fibers.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: tMCK-GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181463405,"sku":"SL101513-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181496173,"sku":"SL101513-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500242_aav-tmck-gfp-aav-serotype-9_SL101513.png?v=1770796258"},{"product_id":"aav-tmck-mcherry-aav-serotype-9-bhv21500243","title":"AAV-tMCK-mCherry (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-tMCK-mCherry\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003etMCK Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500243\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eThe tMCK (truncated muscle creatine kinase) promoter restricts expression to striated muscle, supporting skeletal and cardiac muscle targeting. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003etMCK-mCherry is the encoded payload for this construct. A \u003cstrong\u003emCherry\u003c\/strong\u003e reporter tag is co-expressed to facilitate detection and validation of transduction.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for expression restricted to skeletal muscle fibers.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: tMCK-mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020181528941,"sku":"SL101514-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020181561709,"sku":"SL101514-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500243_aav-tmck-mcherry-aav-serotype-9_SL101514.png?v=1770796258"},{"product_id":"aav-cmv-rluc-aav-serotype-9-bhv21500256","title":"AAV-CMV-Rluc (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CMV-Rluc\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCMV Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500256\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCMV is a strong constitutive viral promoter that drives high-level expression across most cell types; activity can diminish over time in some in vivo settings. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eRluc is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Rluc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182380909,"sku":"SL101534-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182413677,"sku":"SL101534-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500256_aav-cmv-rluc-aav-serotype-9_SL101534.png?v=1770796262"},{"product_id":"aav-cag-rluc-aav-serotype-9-bhv21500258","title":"AAV-CAG-Rluc (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-CAG-Rluc\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eCAG Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500258\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eThis vector encodes a specialized payload for targeted gene modulation, including tools such as RNA interference constructs, genome editors, or other functional effectors. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eCAG is a potent hybrid promoter (CMV enhancer + chicken beta-actin core) widely favored for robust, sustained transgene expression across diverse tissues. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eRluc is the encoded payload for this construct.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: Rluc-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182511981,"sku":"SL101536-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182544749,"sku":"SL101536-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500258_aav-cag-rluc-aav-serotype-9_SL101536.png?v=1770796263"},{"product_id":"aav-ef1-gfp-aav-serotype-9-bhv21500262","title":"AAV-EF1α-GFP (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1α-GFP\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500262\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003eGFP (green fluorescent protein) is a widely used fluorescent reporter for visualizing transduced cells and confirming expression.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: GFP-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182839661,"sku":"SL101623-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182872429,"sku":"SL101623-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500262_aav-ef1-gfp-aav-serotype-9_SL101623.png?v=1770796264"},{"product_id":"aav-ef1-mcherry-aav-serotype-9-bhv21500263","title":"AAV-EF1α-mCherry (AAV Serotype 9)","description":"\u003cdiv class=\"product-detail-large\"\u003e\n \u003cdiv class=\"product-hero-large\"\u003e\n \u003cdiv class=\"hero-badge-large\"\u003eAAV2\/9 Vector\u003c\/div\u003e\n \u003ch2 class=\"hero-title-large\"\u003eAAV-EF1α-mCherry\u003c\/h2\u003e\n \u003cp class=\"hero-subtitle-large\"\u003eEF1α Promoter • pAAV (AAV2 ITR) • Blood-brain barrier crossing with widespread CNS transduction\u003c\/p\u003e\n \u003cp class=\"hero-sku-large\"\u003eBHV21500263\u003c\/p\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-blue\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 3a9 9 0 1 0 9 9c0-.46-.04-.92-.1-1.36a5.389 5.389 0 0 1-4.4 2.26 5.403 5.403 0 0 1-3.14-9.8c-.44-.06-.9-.1-1.36-.1z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eResearch Background\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eFluorescent reporter and control vectors are foundational tools for validating delivery, benchmarking expression levels, and serving as inert controls in experimental designs. \u003cstrong\u003eAAV2\/9 has blood-brain barrier crossing with widespread CNS transduction\u003c\/strong\u003e.\u003c\/p\u003e\n \u003cp\u003eEF1α (elongation factor 1-alpha) is a strong, broadly expressed housekeeping promoter that typically maintains activity better than CMV in long-term in vivo studies. The plasmid backbone is \u003cstrong\u003epAAV (AAV2 ITR)\u003c\/strong\u003e.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-purple\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M13 10V3L4 14h7v7l9-11h-7z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eWhat This AAV Enables\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cdiv class=\"feature-grid-large\"\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eTransgene Function\u003c\/h4\u003e\n \u003cp\u003emCherry is a red fluorescent reporter for cell labeling, tracking, and multi-color imaging experiments.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eExpression Pattern\u003c\/h4\u003e\n \u003cp\u003eExpression is \u003cstrong\u003econstitutive\u003c\/strong\u003e—the transgene is continuously driven by the promoter without requiring an external trigger. The promoter is designed for broad, cell-type-agnostic expression across diverse tissue types.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"feature-item-large\"\u003e\n \u003ch4\u003eCapsid Tropism\u003c\/h4\u003e\n \u003cp\u003eAAV2\/9 crosses the blood-brain barrier efficiently and offers widespread CNS transduction, widely used in neuroscience and gene therapy.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\n \u003cdiv class=\"two-column-large\"\u003e\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-green\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eCommon Applications\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"check-list-large\"\u003e\n\u003cli\u003eIn vivo gene delivery\u003c\/li\u003e\n\u003cli\u003eCell labeling\u003c\/li\u003e\n\u003cli\u003ePromoter testing\u003c\/li\u003e\n\u003cli\u003eTransduction benchmarking\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n\n \u003csection class=\"detail-section-large compact\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-orange\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M12 9v2m0 4h.01m-6.938 4h13.856c1.54 0 2.502-1.667 1.732-3L13.732 4c-.77-1.333-2.694-1.333-3.464 0L3.34 16c-.77 1.333.192 3 1.732 3z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eExperimental Considerations\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cul class=\"bullet-list-large\"\u003e\n\u003cli\u003eAllow sufficient expression time for AAV2\/9 in your target tissue (often 2–4 weeks in vivo).\u003c\/li\u003e\n\u003cli\u003eVerify targeting and expression level in a pilot cohort before committing to large study groups.\u003c\/li\u003e\n\u003cli\u003eUse appropriate controls: mCherry-negative or null-vector matched for serotype and dose.\u003c\/li\u003e\n\u003cli\u003eConfirm expression distribution with immunostaining, in situ hybridization, or imaging as appropriate.\u003c\/li\u003e\n\u003c\/ul\u003e\n \u003c\/section\u003e\n \u003c\/div\u003e\n\n \u003csection class=\"detail-section-large highlight-large\"\u003e\n \u003cdiv class=\"section-header-large\"\u003e\n \u003cdiv class=\"section-icon-large bg-teal\"\u003e\n \u003csvg viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\"\u003e\n \u003cpath d=\"M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z\"\u003e\u003c\/path\u003e\n \u003c\/svg\u003e\n \u003c\/div\u003e\n \u003ch3\u003eControls and Best Practices\u003c\/h3\u003e\n \u003c\/div\u003e\n \u003cdiv class=\"section-body-large\"\u003e\n \u003cp\u003eRecommended controls include: (1) a null or fluorophore-only matched vector to separate delivery effects from payload effects; (2) tissue-matched positive controls to confirm transduction efficiency at your injection coordinates and timepoint; (3) dose-response characterization if the phenotype is sensitive to expression level; and (4) replication across biological cohorts or preparations to confirm robustness.\u003c\/p\u003e\n \u003c\/div\u003e\n \u003c\/section\u003e\n\u003c\/div\u003e\n\u003cstyle\u003e\n .product-detail-large {\n font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;\n color: #1e293b;\n max-width: 1200px;\n margin: 0 auto;\n padding: 2rem;\n font-size: 1.5rem;\n }\n .product-hero-large {\n text-align: center;\n padding: 3rem 2rem;\n background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);\n border-radius: 16px;\n margin-bottom: 3rem;\n border: 2px solid #e2e8f0;\n }\n .hero-badge-large {\n display: inline-block;\n background: #3b82f6;\n color: white;\n padding: 0.5rem 1.5rem;\n border-radius: 30px;\n font-size: 1.25rem;\n font-weight: 700;\n margin-bottom: 1rem;\n }\n .hero-title-large {\n font-size: 3rem;\n font-weight: 800;\n color: #0f172a;\n margin: 0 0 1rem 0;\n }\n .hero-subtitle-large {\n font-size: 1.75rem;\n color: #64748b;\n margin: 0;\n font-weight: 500;\n }\n .detail-section-large {\n background: white;\n border-radius: 16px;\n padding: 2.5rem;\n margin-bottom: 2.5rem;\n border: 2px solid #e2e8f0;\n }\n .detail-section-large.compact { margin-bottom: 0; height: 100%; }\n .detail-section-large.highlight-large {\n background: #f8fafc;\n border-left: 6px solid #14b8a6;\n }\n .section-header-large {\n display: flex;\n align-items: center;\n gap: 1.25rem;\n margin-bottom: 1.5rem;\n padding-bottom: 1.25rem;\n border-bottom: 2px solid #f1f5f9;\n }\n .section-icon-large {\n width: 4rem;\n height: 4rem;\n border-radius: 12px;\n display: flex;\n align-items: center;\n justify-content: center;\n flex-shrink: 0;\n }\n .section-icon-large svg { width: 2.25rem; height: 2.25rem; color: white; }\n .bg-blue { background: #3b82f6; }\n .bg-purple { background: #8b5cf6; }\n .bg-green { background: #10b981; }\n .bg-orange { background: #f59e0b; }\n .bg-teal { background: #14b8a6; }\n .detail-section-large h3 { font-size: 2.25rem; font-weight: 800; color: #0f172a; margin: 0; }\n .section-body-large p { font-size: 1.5rem; line-height: 1.6; color: #334155; margin: 0 0 1.5rem 0; }\n .section-body-large p:last-child { margin-bottom: 0; }\n .section-body-large strong { color: #0f172a; font-weight: 700; }\n .feature-grid-large { display: flex; flex-direction: column; gap: 2rem; }\n .feature-item-large h4 { font-size: 1.75rem; font-weight: 700; color: #0f172a; margin: 0 0 0.75rem 0; }\n .feature-item-large p { font-size: 1.5rem; line-height: 1.6; color: #475569; margin: 0; }\n .two-column-large { display: grid; grid-template-columns: 1fr 1fr; gap: 2.5rem; margin-bottom: 2.5rem; }\n .check-list-large { list-style: none; padding: 0; margin: 0; }\n .check-list-large li {\n padding: 1rem 0 1rem 3rem;\n position: relative;\n font-size: 1.5rem;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n line-height: 1.5;\n }\n .check-list-large li:last-child { border-bottom: none; }\n .check-list-large li::before {\n content: \"✓\";\n position: absolute;\n left: 0;\n color: #10b981;\n font-weight: 800;\n font-size: 2rem;\n top: 0.875rem;\n }\n .bullet-list-large { list-style: none; padding: 0; margin: 0; }\n .bullet-list-large li {\n padding: 1rem 0 1rem 2.5rem;\n position: relative;\n font-size: 1.5rem;\n line-height: 1.6;\n color: #334155;\n border-bottom: 2px solid #f8fafc;\n }\n .bullet-list-large li:last-child { border-bottom: none; }\n .bullet-list-large li::before {\n content: \"•\";\n position: absolute;\n left: 0;\n color: #f59e0b;\n font-weight: 900;\n font-size: 2.5rem;\n line-height: 1;\n top: 0.5rem;\n }\n @media (max-width: 1024px) { .two-column-large { grid-template-columns: 1fr; } }\n @media (max-width: 768px) {\n .product-detail-large { padding: 1.5rem; font-size: 1.25rem; }\n .hero-title-large { font-size: 2.25rem; }\n .hero-subtitle-large { font-size: 1.5rem; }\n .detail-section-large h3 { font-size: 1.875rem; }\n .section-body-large p, .feature-item-large p,\n .check-list-large li, .bullet-list-large li { font-size: 1.25rem; }\n .detail-section-large { padding: 1.75rem; }\n }\n\n .hero-sku-large { font-size: 1.1rem; color: #94a3b8; margin: 0.75rem 0 0 0; letter-spacing: 0.05em; font-weight: 500; }\n\u003c\/style\u003e","brand":"Biohippo Inc","offers":[{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 30 uL (Std Pack)","offer_id":53020182905197,"sku":"SL101624-30UL","price":488.0,"currency_code":"USD","in_stock":true},{"title":"AAV2\/9 \/ 1.00E+13 VG\/mL \/ 10 uL (Trial Pack)","offer_id":53020182937965,"sku":"SL101624-10UL","price":168.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/BHV21500263_aav-ef1-mcherry-aav-serotype-9_SL101624.png?v=1770796265"}],"url":"https:\/\/www.ebiohippo.com\/collections\/aav9-vectors.oembed?page=2","provider":"BioHippo","version":"1.0","type":"link"}